Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
1.540
+0.090 (6.21%)
At close: May 12, 2025, 4:00 PM
1.472
-0.068 (-4.42%)
After-hours: May 12, 2025, 6:00 PM EDT
Editas Medicine Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Editas Medicine stock have an average target of 7.09, with a low estimate of 3.00 and a high estimate of 15. The average target predicts an increase of 360.39% from the current stock price of 1.54.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Editas Medicine stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 7 | 7 | 7 | 7 | 7 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 15 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +94.81% | Apr 28, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +224.68% | Dec 16, 2024 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Dec 16, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $5 → $4 | Hold | Maintains | $5 → $4 | +159.74% | Dec 13, 2024 |
| Barclays | Barclays | Hold Maintains $5 → $3 | Hold | Maintains | $5 → $3 | +94.81% | Dec 13, 2024 |
Financial Forecast
Revenue This Year
9.58M
from 32.31M
Decreased by -70.36%
Revenue Next Year
7.00M
from 9.58M
Decreased by -26.91%
EPS This Year
-1.55
from -2.88
EPS Next Year
-1.08
from -1.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 44.1M | 22.6M | 26.3M | ||
| Avg | 9.6M | 7.0M | 8.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 36.5% | 135.7% | 274.9% | ||
| Avg | -70.4% | -26.9% | 25.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.05 | -0.62 | -0.89 | ||
| Avg | -1.55 | -1.08 | -1.19 | ||
| Low | -2.01 | -1.74 | -1.66 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.